🇺🇸 FDA
Patent

US 8940773

Prolyl hydroxylase inhibitors and methods of use

granted A61KA61K31/4418A61K31/4433

Quick answer

US patent 8940773 (Prolyl hydroxylase inhibitors and methods of use) held by Akebia Therapeutics, Inc. expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Akebia Therapeutics, Inc.
Grant date
Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/4418, A61K31/4433, A61P, A61P1/04